SSA
AMLX icon

Schonfeld Strategic Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
77,794
+56,742
+270% +$798K 0.01% 1054
2025
Q4 		$254K Sell
21,052
-22,585
-52% -$307K ﹤0.01% 1627
2025
Q3 		$593K Sell
43,637
-602,806
-93% -$5.67M ﹤0.01% 1620
2025
Q2 		$4.14M Buy
646,443
+529,303
+452% +$2.57M 0.03% 629
2025
Q1 		$415K Sell
117,140
-76,791
-40% -$273K ﹤0.01% 1662
2024
Q4 		$733K Buy
193,931
+27,502
+17% +$129K ﹤0.01% 1252
2024
Q3 		$539K Buy
166,429
+144,829
+671% +$326K ﹤0.01% 1401
2024
Q2 		$41K Buy
+21,600
New +$41.9K ﹤0.01% 1953
2023
Q4 		– Sell
-137,523
Closed -$2.52M – 1848
2023
Q3 		$2.52M Sell
137,523
-72,862
-35% -$1.54M 0.02% 754
2023
Q2 		$4.54M Sell
210,385
-74,620
-26% -$2.02M 0.04% 516
2023
Q1 		$8.36M Buy
285,005
+173,081
+155% +$6.01M 0.08% 328
2022
Q4 		$4.14M Sell
111,924
-213,776
-66% -$7.59M 0.03% 541
2022
Q3 		$9.17M Buy
+325,700
New +$8.13M 0.08% 340

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Schonfeld Strategic Advisors's AMLX Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 270% in Q1 2026, buying an estimated $798K and bringing the position to 77,794 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #1054.

Schonfeld Strategic Advisors first reported a position in AMLX in Q3 2022 and has held it in 13 quarters since. The position peaked at $9.17M in Q3 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Schonfeld Strategic Advisors held 77,794 shares of Amylyx Pharmaceuticals worth $1.08M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 56,742 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $798K.
  • Amylyx Pharmaceuticals made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1054 holding.
  • Schonfeld Strategic Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Schonfeld Strategic Advisors's Amylyx Pharmaceuticals position peaked at $9.17M in Q3 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.